Mark Joseph Nejmeh
P.O. Box 589
Clifton, New Jersey 07012
Telephone: 732-995-3914
Email: research@warrantwire.com
Plaintiff, self-represented

UNITED STATES DISTRICT COURT
DISTRICT OF NEVADA

MARK JOSEPH NEJMEH, Plaintiff, v. **THERIVA BIOLOGICS, INC., STEVEN A. SHALLCROSS, JEFFREY J. KRAWS, JEFFREY WOLF and JOHN MONAHAN,** Defendants.	**Case No. 3:26-cv-00705-ART-CSD** **EXHIBIT A-3** **DECLARATION OF MARK JOSEPH NEJMEH**

I, Mark Joseph Nejmeh, declare:

1. I am the Plaintiff in this action. I make this declaration from my own knowledge and from the documents identified below.

2. Exhibit A-1 is a true copy of Theriva Biologics, Inc.'s Form 8-K filed with the Securities and Exchange Commission on November 20, 2026, Accession No. 0001104659-26-130644, with its Exhibit 99.1 press release, as published on the SEC's EDGAR system.

3. Exhibit A-2 is a true copy of Theriva Biologics, Inc.'s Form 8-K filed with the Securities and Exchange Commission on November 18, 2026, Accession No. 0001104659-26-129752, as published on the SEC's EDGAR system.

4. On November 23, 2026, Elizabeth V. Young of Blank Rome LLP, counsel for Theriva, sent me an email with a proposed stipulation under which Theriva would consent to the filing of the Second Amended Verified Complaint and keep its December 1, 2026 response date. Paragraph 4 of the proposed stipulation read: "Plaintiff agrees that

he will not seek any further leave to amend his complaint in this Action." I do not agree to that term.

5. Documents already filed in this case, including the proxy statement for the November 18, 2026 meeting (ECF No. 42-2), are cited by their ECF numbers and are not attached again.

I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct.

Executed on November 23, 2026.

/s/ Mark Joseph Nejmeh
Mark Joseph Nejmeh